Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS25713)
King's Prize Fellowship (x)
Ohio Department of Higher Education-Third Frontier Program (x)
Brumagin-Nelson Fund (x)
Kaneko Family Fund (x)
Hong Kong Spinal Cord Injury Fund (x)
Brotman Baty Institute (x)
Medical Research Council (MR/S011110/1)
Article History
Received: 1 March 2021
Accepted: 20 May 2021
First Online: 2 June 2021
Declarations
:
: A patent (9,937,242) filed by CWRU has been granted for ISP and licensed to NervGen Pharma Corp. The remaining authors declare no competing conflicts of interest.